StockData

Incannex Healthcare vs Kazia Therapeutics

IXHL and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IXHL and KZIA compare

Incannex Healthcare scores higher on the StockData Score (7 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIXHLKZIA
Size and price
Market cap$21.8M–
Share price$1.74$5.31
Change, 1 year−83.5%−15.3%
Change, 5 years–−98.9%
Beta (5Y)2.404.08
Employees1214
StockData Score
Total score7 (better)1
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/B0.3×–
FCF yield−14.6%–
Growth
Revenue growth (TTM)–−98.2%
Profitability
Net margin–−49291%
Return on equity−20.7%–
Return on invested capital−1945%–
Financial health
Debt / equity0.00–
Current ratio67.79 (better)2.87
Altman Z-score−0.22–
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−42.2%–
Shareholder yield−42.2%–
Ownership
Held by institutions3.6%0.45%
Held by insiders–0.29%
Superinvestors holding–1

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.